Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia

Clinical Pharmacology and Therapeutics
Sabine L A PlasschaertEveline S J M de Bont

Abstract

Our objective was to investigate the effect of single nucleotide polymorphisms (SNPs) in the P-glycoprotein MDR1 gene on vincristine pharmacokinetics and side effects in childhood acute lymphoblastic leukemia. From 52 of 70 children who participated in a previous study on vincristine pharmacokinetics, patient material was available for investigation of the MDR1 genetic variants. The SNPs C3435T and G2677T were determined by use of polymerase chain reaction-restriction fragment length polymorphism. Vincristine side effects were scored retrospectively from patient records. No association was observed between C3435T or G2677T and vincristine pharmacokinetic variables. When haplotypes were assigned, haplotype 1/1 carriers (3435C/2677G) showed a longer elimination half-life than noncarriers (1156 versus 805 minutes, P =.038). In contrast, haplotype 1/2 carriers (3435T/2677G) had a shorter elimination half-life than noncarriers (805 versus 1180 minutes, P =.044). However, this significance was lost after Bonferroni correction for multiple testing. The haplotypes did not affect the other pharmacokinetic parameters, such as clearance and area under the concentration-time curve, suggesting that the observed effect on elimination half-li...Continue Reading

Citations

Jan 30, 2009·JAMA : the Journal of the American Medical Association·Jun J YangMary V Relling
Feb 3, 2011·European Journal of Clinical Pharmacology·Francesco BellantiOscar Della Pasqua
Aug 27, 2014·Pharmacogenomics·Elixabet Lopez-LopezAfrica Garcia-Orad
Aug 28, 2014·Expert Opinion on Drug Metabolism & Toxicology·Oliver Bruhn, Ingolf Cascorbi
May 1, 2010·Expert Opinion on Pharmacotherapy·Nathan D MeekerJoshua D Schiffman
Jun 21, 2005·British Journal of Clinical Pharmacology·Florent PuissetHenri Roché
Jul 18, 2006·British Journal of Clinical Pharmacology·Alan V Boddy
Oct 13, 2007·Expert Opinion on Pharmacotherapy·Lea Cunningham, Richard Aplenc
May 14, 2005·Pharmacology & Therapeutics·Thomas Efferth, Manfred Volm
Jun 10, 2008·British Journal of Haematology·Gudmar LönnerholmSiebold S N de Graaf
Dec 29, 2017·The Pharmacogenomics Journal·Ángela Gutierrez-CaminoAfrica Garcia-Orad
Apr 20, 2007·Journal of Clinical Pharmacology·Dominique Levêque, François Jehl
Sep 29, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Christiane Pauli-Magnus, Peter J Meier
Nov 8, 2008·Pediatric Blood & Cancer·Nikolaos V KarathanasisMaria Kalmanti
Nov 8, 2008·Journal of Pediatric Hematology/oncology·Marie Louise DavidsenKjeld Schmiegelow
Jul 10, 2009·Pediatric Blood & Cancer·Andrew Moore, Ross Pinkerton
Apr 27, 2010·Journal of Pediatric Hematology/oncology·Manuel DieziMaja Beck-Popovic
Feb 27, 2007·Cancer Metastasis Reviews·Ying Huang
Jan 18, 2006·Drug Metabolism and Pharmacokinetics·Toshiyuki Sakaeda
Nov 5, 2019·Pediatric Hematology and Oncology·Nassr NamaShahrad Rod Rassekh
Mar 16, 2011·Cancer Chemotherapy and Pharmacology·Romain GuilhaumouCaroline Solas
Jul 8, 2016·Journal of Clinical Pharmacology·Frédérique RodieuxJohannes N van den Anker
Jan 4, 2019·Paediatric Drugs·Radna Minou Oostveen, Kathy Pritchard-Jones
Jan 19, 2021·Expert Opinion on Drug Metabolism & Toxicology·Henrike Bruckmueller, Ingolf Cascorbi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
S Cortijo-CascajaresA Herreros de Tejada
Genome Medicine
Stéphanie Dulucq, Maja Krajinovic
© 2021 Meta ULC. All rights reserved